Positive News SentimentPositive NewsNASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $1.73 -0.36 (-17.22%) Closing price 04:00 PM EasternExtended Trading$1.75 +0.02 (+0.92%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About KALA BIO Stock (NASDAQ:KALA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KALA BIO alerts:Sign Up Key Stats Today's Range$1.63▼$2.0850-Day Range$0.08▼$10.0052-Week Range$1.63▼$1,030.00Volume314,159 shsAverage Volume150,149 shsMarket Capitalization$32.16 millionP/E RatioN/ADividend YieldN/APrice Target$1,018.75Consensus RatingHold Company Overview KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis. Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions. These include formulations under development for dry eye disease and post-operative ocular inflammation, each leveraging the company’s nanoparticle platform to achieve higher local drug concentrations while potentially reducing systemic exposure. Preclinical and clinical programs are also exploring additional indications in retinal and anterior segment disorders. Founded in 2014 and headquartered in Watertown, Massachusetts, KALA Bio conducts research and development activities primarily in the United States. The company collaborates with academic institutions, specialty pharmacies and contract research organizations to support its clinical programs and regulatory filings. To broaden its global footprint, KALA Bio is evaluating strategic partnerships for potential expansion into European and Asian markets.AI Generated. May Contain Errors. Read More KALA BIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreKALA MarketRank™: KALA BIO scored higher than 63% of companies evaluated by MarketBeat, and ranked 342nd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingKALA BIO has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.Upside PotentialKALA BIO has a consensus price target of $1,018.75, representing about 58,787.3% upside from its current price of $1.73.Amount of Analyst CoverageKALA BIO has only been the subject of 1 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.36% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KALA BIO has recently decreased by 8.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentKALA BIO has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for KALA BIO this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for KALA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have not sold or bought any company stock.Percentage Held by Insiders2.24% of the stock of KALA BIO is held by insiders.Percentage Held by Institutions24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KALA Stock News HeadlinesKALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 markMay 8, 2026 | msn.comKALA BIO Announces Reverse Stock SplitMay 7, 2026 | globenewswire.comThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Checklist covers the 7 most critical checks in about 30 seconds, helping you catch losing trades before you enter them. Normally $29.97, it's available free for a limited time. Download it now and run it before every trade.June 30 at 1:00 AM | Profits Run (Ad)How smart traders spot penny stock breakouts fastMay 1, 2026 | msn.comKala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic MedicineApril 21, 2026 | globenewswire.comKala Bio Delays 2025 Annual Report FilingApril 6, 2026 | theglobeandmail.comKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development OpportunitiesApril 1, 2026 | globenewswire.comKALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveMarch 30, 2026 | globenewswire.comSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $27.7950 at the beginning of the year. Since then, KALA shares have decreased by 93.8% and is now trading at $1.73. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($8.50) by $8.36. When did KALA BIO's stock split? KALA BIO's stock reverse split before market open on Monday, May 11th 2026.The 1-50 reverse split was announced on Thursday, May 7th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings5/15/2026Today6/30/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 KALA's financial health is in the Red zone, according to TradeSmith. KALA has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALA CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees30Year Founded2009Price Target and Rating Average Price Target for KALA BIO$1,018.75 High Price Target$1,750.00 Low Price Target$75.00 Potential Upside/Downside+58,787.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($96.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,336.10% Return on Assets-94.85% Debt Debt-to-Equity RatioN/A Current Ratio7.91 Quick Ratio7.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.56 per share Price / Book0.14Miscellaneous Outstanding Shares18,590,000Free Float18,174,000Market Cap$32.16 million OptionableNot Optionable Beta-2.40 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:KALA) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredForget the million-dollar nest egg — you only need THIS muchNearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't ...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
